Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care

MedXY Editorial Team•Mar 3, 2026•Allergy & Immunology

Multimorbidity is near-ubiquitous in severe asthma, necessitating a shift from asthma-centric to patient-centric management models.
The SHARP central database study identified three stable comorbidity clusters across Europe: steroid-induced (osteoporosis/weight gain), atopic (eczema/rhinitis), and sinonasal (sinusitis/nasal polyps).
The ‘Steroid-associated Multimorbidity Phenotype’ (MMP ster) represents the most clinically burdened group, with the worst lung function, highest exacerbation rates, and highest BMI.
Recognizing these multimorbidity phenotypes allows for targeted interventions and may mitigate the iatrogenic impact of long-term oral corticosteroid use.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Multimorbidity is near-ubiquitous in severe asthma, necessitating a shift from asthma-centric to patient-centric management models.
The SHARP central database study identified three stable comorbidity clusters across Europe: steroid-induced (osteoporosis/weight gain), atopic (eczema/rhinitis), and sinonasal (sinusitis/nasal polyps).
The ‘Steroid-associated Multimorbidity Phenotype’ (MMP ster) represents the most clinically burdened group, with the worst lung function, highest exacerbation rates, and highest BMI.
Recognizing these multimorbidity phenotypes allows for targeted interventions and may mitigate the iatrogenic impact of long-term oral corticosteroid use.